Stockreport

Vir Biotechnology Announces First Patient Dosed in Part 3 of Phase 1 Trial of PSMA-Targeting PRO-XTEN® Dual-Masked T-Cell Engager VIR-5500 in Combination with Androgen Receptor Pathway Inh...

Vir Biotechnology, Inc.  (VIR) 
PDF – Clinical trial builds on encouraging Phase 1 data of monotherapy VIR-5500 in late-line patients presented in January 2025 SAN FRANCISCO, October 09, 2025 BUSINESS W [Read more]